Skip to main content
Erschienen in: Infection 6/2006

Open Access 01.12.2006 | Brief Report

Primary Invasive Aspergillosis of the Digestive Tract: Report of Two Cases and Review of the Literature

verfasst von: P. Eggimann, J.-C. Chevrolet, M. Starobinski, P. Majno, M. Totsch, B. Chapuis, D. Pittet

Erschienen in: Infection | Ausgabe 6/2006

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background:

Disseminated aspergillosis is thought to occur as a result of vascular invasion from the lungs with subsequent bloodstream dissemination, and portals of entry other than sinuses and/or the respiratory tract remain speculative.

Methods:

We report two cases of primary aspergillosis in the digestive tract and present a detailed review of eight of the 23 previously-published cases for which detailed data are available.

Results and Conclusion:

These ten cases presented with symptoms suggestive of typhlitis, with further peritonitis requiring laparotomy and small bowel segmental resection. All cases were characterized by the absence of pulmonary disease at the time of histologically-confirmed gastrointestinal involvement with vascular invasion by branched Aspergillus hyphae. These cases suggest that the digestive tract may represent a portal of entry for Aspergillus species in immunocompromised patients.

Introduction

Aspergillus spores are ubiquitous, and once aerosolized, they may colonize the airways and related structures, such as the nose and facial sinuses [1]. Further immunosuppression, such as severe and prolonged neutropenia, markedly increases the risk for invasive disease characterized by tissue invasion and secondary bloodstream dissemination [1]. Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger are responsible for the majority of invasive diseases [24]. Invasive aspergillosis is reported to occur in fewer than 1% of patients infected by human immunodeficiency virus (HIV), in 1–5% of liver transplant recipients, in 3–7% of allogenic bone marrow transplant recipients, but in up to 10% of patients with hematological malignancies or lung transplants, and as high as 14% of heart transplant recipients [2–7].
Invasive pulmonary aspergillosis accounts for 90–98% of invasive infections. Extra-pulmonary aspergillosis may be present in 25–60% of cases and is almost universally described in the context of disseminated diseases [2, 815]. Although rarely documented before autopsy, these conditions usually result from bloodstream dissemination secondary to vascular invasion at the primary site of infection [16]. Isolated extra-pulmonary aspergillosis located in the central nervous system, the skin, the liver, the urinary tract and the digestive tract has only been mentioned in case reports, but potential portals of entry other than the respiratory tract are speculative [2, 3, 17]. We report two cases of primary invasive aspergillosis of the digestive tract and review the literature on Aspergillus spp. gastrointestinal involvement.

Methods

Our objective was to identify lower digestive tract involvement reported in series of invasive aspergillosis and secondly, to identify previously-published cases with a possible diagnosis of aspergillosis at this site. We searched the English-language literature from 1960 to 2005, December, for reports of aspergillosis with digestive tract involvement through an electronic search of the MEDLINE (National Library of Medicine, Bethesda, MD, USA) database using key words “aspergillosis”, “invasive aspergillosis”, “disseminated disease”, “extra-pulmonary aspergillosis” and “digestive tract aspergillosis” and the reference lists of retrieved articles, including reviews. Cases were included if the diagnosis of primary invasive aspergillosis of the bowel was defined as histologic evidence of Aspergillus hyphae in a segment of the bowel biopsy with mucosal alteration and tissue destruction and/or tissue invasion with microvascular involvement. Cases with isolated involvement of the upper digestive tract were excluded.

Case Reports

Case 1

A 65-year-old man presented with septic shock attributed to Proteus vulgaris primary bacteremia without clinical focus of infection. It occurred on day 6 after admission for transformation of a myelodysplasic syndrome into acute myeloid leukemia for which he received high-dose cytarabine with idarubicin as induction therapy. He responded to empirical broad spectrum antibiotics within 48 h. Fever recurred on day 10 with abdominal pain, and septic shock developed the following day. On day 12, emergency laparotomy showed a necrotic mass of the jejunum which was resected. Direct histologic examination showed branched hyphae with transmural involvement and vascular invasion. After transient improvement for 48 h, multiple organ failure developed. Macroscopic Aspergillus colonies appeared on the surgical stomas at day 14 and the patient died on day 16 despite intensive support and amphotericin B therapy. Autopsy showed disseminated aspergillosis with several new segmental necroses of the small bowel and multiple emboli of fungal material in several organs including the lungs. A detailed examination of the lungs did not show any consolidated aera. A. fumigatus was isolated from peroperative and autopsy cultures.

Case 2

A 52-year-old man presented with septic shock due to Pseudomonas aeruginosa primary bacteremia without clinical focus of infection. The symptoms occurred on day 14 after admission for transformation of a myelodysplasic syndrome into acute myelocytic leukemia for which he received high-dose cytarabine with idarubicin as induction therapy. He responded to empirical broad spectrum antibiotics within 48 h. Fever relapsed on day 25 with abdominal pain. A CT scan excluded lung infiltrates and confirmed the diagnostic of typhlitis. On day 30, a laparotomy performed for acute peritonitis revealed four masses in the ileon. Histology showed branched hyphae (A. fumigatus by culture) with transmural involvement and vascular invasion (Figure 1). A second CT scan excluded lung involvement. Therapy with amphotericin B (2 g over 28 days) was initiated and the patient made a full recovery on day 45. Two months later he died from hemorrhage during induction therapy for autologous bone marrow transplantation. Autopsy showed no recurrence of aspergillosis.

Results

Of 23 cases of possible primary invasive aspergillosis of the digestive tract identified in the literature [5, 1214, 1822], details were available for only eight of them [2330] (Table 1).
Table 1
Selected characteristics of ten patients with primary digestive invasive aspergillosis.
 
Case report
Case report
Case 37-1976 [23]
Weingard [24]
Cohén [25]
Marterre [26]
Catalano [27]
Shah [28]
Sousa [29]
Trésallet [30]
Age (years)
63
52
4 weeks
38
33
8
58
68
21
57
Underlying disease
AML
AML
AML
ALL
AML
AML
AML
AML
Aplastic anemia
Lymphoma
Documentation
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Histology + culture
Previous infection
Bacteremia
Bacteremia
Bacteremia
Bacteremia
Fever of unknown origin
Bacteremia
Fever of unknown origin
Suspected line infection
Fever of unknown origin
Fever of unknown origin
Microorganisms
Proteus vulgaris
Pseudomonas aeruginosa
Staphylococcus aureus
Klebsiella oxytoca; Enterococcus faecatis
Pseudomonas aeruginosa
Chemotherapy
Cytarabine, idarubicin
Cytarabine, idarubicin
Cytarabine, daunorubicin
Cytarabine, adriamicin
Cytarabine, daunorubicin
Vincristin
Cytarabine, daunorubicin
Cytarabine, idarubicin
Cyclosporin A
Cytarabine, etoposide
Days after chemotherapy
13
14
8 (second cycle)
19 (second cycle)
24
23
15
11
28
Not specified (induction)
Neutropenia at diagnosis
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Antifungal prophylaxis
No
No
No
Not specified
Not specified
Not specified
Yes
Not specified
Not specified
Not specified
Number of previous antibiotics
3
3
3
2
5
3
Several
4
Several
3
Antimicrobial agents
Ciprofloxacin, gentamicin, metronidazole
Meropenem, amikacin, teicoplanin
Carbenicillin, gentamicin, oxacillin
Ceftazidime, amikacin
Ceftazidime, amikacin
Ceftazidime, tobramycin, ticarcillin
Not specified
Cefepime, metronidazole, gentamicin, vancomycin
Not specified
Imipenem, gentamicin, metronidazole
Prior exposure to amphotrericin B
No
Yes
No
No
Yes
No
No
No
No
No
Clinical presentation
Relapsing fever, ileus, peritonitis
Relapsing fever, ileus, bloody diarrhea, peritonitis
Relapsing fever, peritonitis
Relapsing fever, ileus, bloody diarrhea, peritonitis
Relapsing fever, watery diarrhea, peritonitis
Relapsing fever, ileus, peritonitis
Relapsing fever, digestive hemorrhage, peritonitis
Persisting fever, peritonitis
Persisting fever, peritonitis
Persisting fever, peritonitis
Serology
Antigenemia
6.2 ng/ml (ELISA)
Secondary dissemination
Lung
No
Lung, liver
Lung
Lung, liver
No
Not specified
Not specified
Not specified
No
No. of surgical interventions
1
2
1
1
2
5
1
1
1
1
Days after chemotherapy
12
13
8
19
24
23
15
14
28
Not specified
Bowel excision
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Antifungal treatment
Amphotericin B
Amphotericin B
Not specified
Not specified
Not specified
Voriconazole
Outcome at 28 days
Death
Survival
Death
Survival
Death
Survival
Death
Death
Death
Survival
AML: acute myeloid leukemia; ALL: acute lymphoid leukemia
Nine of ten patients presented with acute hematologic malignancy, and eight received high-dose cytarabine known to be associated with diffuse mucositis. Six presented a prior episode of bacteremia during neutropenia. All ten received a combination of antibiotics with broad spectrum coverage within the 2 weeks before the onset of the abdominal complication, and all presented with abdominal symptoms suggestive of typhlitis, with digestive hemorrhage in three. Laparotomy was performed for acute peritonitis and showed transmural necrosis of the small bowel requiring segmental resection in all cases. Histology consisted in multiple lesions from superficial ulceration to transmural necrosis and vascular thrombosis with tissue invasion by branched hyphae of Aspergillus spp. were present in all cases (Figure 1). All cases were characterized by the absence of pulmonary disease at time of histologically-confirmed digestive aspergillosis. Serology and antigenemia was either not available or not performed in all but one cases and death occurred in six of ten patients (60%).
Of 155 clinical studies retrieved from our review of the literature, 25 included more than 25 cases of invasive aspergillosis in non-HIV infected adult patients with details on the distribution of organs involved (Table 2). There were 6 autopsy series [1113, 18, 31, 32], 11 retrospective series [5, 14, 15, 19, 3339] and 8 prospective series [2022, 4044].
Table 2
Invasive aspergillosis: organ distribution and mortality; 1960–2005. Studies including more than 25 adult patients.
     
Organ distribution
  
Authors
N
Mortality
Lung
Disseminated
CNS
Digestive
Primary digestive
Autopsy
Young et al. [12]
98
100%
92 (94%)
34 (35%)
13 (13%)
21 (21%)
3 (3%)
Meyer et al. [13]
93
100%
90 (98%)
23 (35%)
9 (10%)
9 (10%)
1 (1%)
Boon et al. [11]
32
100%
32 (100%)
20 (63%)
16 (50%)
15 (53%)
0
Vogeser et al. [18]
27
100%
23 (85%)
16 (59%)
12 (44%)
7 (26%)
1 (4%)
Vogeser et al. [31]
48
100%
41 (85%)
28 (58%)
21 (44%)
1 (2%)
0
Hori et al. [56]
107
100%
105 (98%)
52 (52%)
22 (21%)
12 (11%)
0
Total
405
100%
383 (95%)
176 (43%)
93 (23%)
67 (17%)
5 (1%)
Retrospectiva
Fisher et al. [14]
91
88%
83 (91%)
20 (22%)
13 (14%)
5 (5%)
1 (1%)
Albelda et al. [15]
26
62%
26 (100%)
NS
NS
NS
NS
Morrison et al. [5]
93
62%
87 (95%)
43 (47%)
21 (23%)
NS
1 (1%)
Horvath and
69
52%
49 (71%)
NS
NS
NS
NS
Dummer [33]
Janssen et al. [34]
25
92%
25 (100%)
8 (32%)
3 (12%)
4 (28%)
0
Caillot et al. [35]
37
27%
37 (100%)
8 (22%)
0
0
0
Kaiser et al. [36]
35
97%
33 (94%)
8 (23%)
1 (3%)
0
0
Abbasi et al. [37]
66
85%
46 (70%)
23 (35%)
9 (14%)
0
0
Lortholary et al. [38]
31
45%
28 (90%)
7 (23%)
4 (13%)
0
0
Nosari et al. [39]
61
48%
56 (92%)
20 (33%)
5 (8%)
0
0
Pagano et al. [19]
391
51%
332 (85%)
NS
37 ( 9%)
9 (2%)
4 (1%)
Total
925
60% 555/925
802 (87%)
137/438 (31%)
92/829 (11%)
18/737 (2%)
6/829 (0.7%)
Prospective
Ringden et al. [40]
32
34%
29 (91%)
NS
NS
0
NS
Denning et al. [20]
76
32%
51 (67%)
NS
8 (11%)
NS
1 (1.3%)
Stevens et al. [21]
125
34%
90 (72%)
24 (19%)
8 (6%)
0
1 (0.8%)
Denning et al. [22]
123
64%
106 (87%)
33 (27%)
10 (8%)
0
1 (0.8%)
Patterson et al. [41]
595
51%
330 (56%)
148 (25%)
34 (6%)
NS
NS
Denning et al. [42]
116
58%
81 (70%)
6 (5%)
19 (16%)
0
0
Bowden et al. [44]
174
53%
107 (62%)
NS
12 (7%)
NS
NS
Herbrecht et al. [43]
277
35%
240 (87%)
15 (5%)
10 (4%)
NS
NS
Total
1,518
47%
1,034 (64%)
226/1,236 (18%)
101/1,486 (7%)
0/396 (0%)
3/440 (0.7%)
  
716/1518
     
All studies
2,848
59%
2,219 (78%)
539/2,079 (26%)
296/2,720 (11%)
85/1,538 (5.5%)
14/1,674 (0.8%)
  
1676/2848
     
NS: not specified
The proportion of cases with a definite diagnosis was 100% in autopsy series and 73% (60–92%) and 65% (31–88%) in retrospective, and prospective series, respectively. The number of cases where the diagnosis was made before death increased from 23% (14–56%) in autopsy series, 76% (28–100%) in retrospective and 99.9% (99–100%) in prospective series. Mortality averaged 60% (27–88%) in retrospective and 47% (32–64%) in prospective series. This may indicate that patients included in prospective studies were less critically ill, or may have benefited from early presumptive antifungal therapy. Case-fatality rate was recently confirmed to be highest in bone marrow transplant recipients (87%) and among patients with central nervous system involvement (88%) [45]. A large number of patients with solid organ transplant may have contributed to the higher survival rate reported in prospective series.
Invasive pulmonary aspergillosis accounted for a majority of cases. Bowel involvement during disseminated disease was not reported in prospective series and in only 2% of cases in retrospective series (0–28%). However, it was reported in 17% (2–53%) of cases included in the autopsy series. Apart from 14 cases for which no details were available, invasion of the digestive tract was always reported in the context of disseminated disease [1114, 18, 20, 21, 34, 40, 46]. A mixed infection with Candida species was reported in series where more details were available [12, 47]. A digestive hemorrhage was reported in most cases, but was not considered specific.

Comment

Invasive aspergillosis is almost exclusively considered as a pulmonary disease with secondary hematogenous dissemination [1, 5]. Fungal infections of the small and large intestine are rare [47]. However, Aspergillus spores are not only inhaled but also ingested, and isolated aspergillosis of the upper digestive tract has been described [48]. In two reviews covering more than 3,000 cases collected from several hundreds of articles over three decades, Denning suggested that, although never demonstrated, the gastrointestinal tract may be considered as a potential portal of entry for Aspergillus spp. [2, 3].
In contrast to Candida spp., Aspergillus spores may not survive or meet favorable conditions to develop on the mucosal surfaces of the digestive tract. However, large ulcers, such as those described as occurring after high-dose cytarabine-related mucositis, may be colonized by Aspergillus spores [48]. This may also be the case for patients developing a neutropenic or necrotizing enterocolitis, also referred to as typhlitis. This defines an abdominal complication occurring in neutropenia and induced by chemotherapy [49]. It complicates 5–30% of treatments, including those with high-dose cytarabine, with variable clinical manifestations ranging from mild gastrointestinal symptoms to life-threatening intestinal necrosis with perforation and secondary peritonitis [50, 51]. The latter condition mandates a surgical approach and has been associated with mortality rates of over 50% [52, 53]. Although not specific, abdominal CT scan may be suggestive. The eventual value of Aspergillus serology and antigenemia has not been studied in this context. Diffuse dilatation with edema of the bowel walls, predominantly located in the caecum, with some degree of hemorrhage and necrosis are common pathological findings [54]. As described in the ten above-mentioned cases, bowel necrosis is associated with the invasion of a poorly vascularized wall by gram-negative bacilli and yeast after breakdown of the normal flora [52, 55].
In conclusion, we report two cases of possible primary digestive aspergillosis. These two cases and the eight previously published suggest that the digestive tract may represent a portal of entry for Aspergillus species in immunocompromised patients.

Acknowledgments

The authors are indebted to the team of the Medical Intensive Care Unit, and the members of the Bone Marrow Transplant Unit, University of Geneva Hospitals. We thank also Rosemary Sudan for providing editorial assistance.
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://​creativecommons.​org/​licenses/​by-nc/​2.​0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Unsere Produktempfehlungen

Neuer Inhalt

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Bartlett JG: Aspergillosis update. Medicine (Baltimore) 2000; 79: 281–302.CrossRef Bartlett JG: Aspergillosis update. Medicine (Baltimore) 2000; 79: 281–302.CrossRef
2.
Zurück zum Zitat Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1201.PubMed Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1201.PubMed
3.
Zurück zum Zitat Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–615.PubMed Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–615.PubMed
4.
Zurück zum Zitat Marr KA, Patterson T, Denning D: Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875–894.CrossRefPubMed Marr KA, Patterson T, Denning D: Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875–894.CrossRefPubMed
5.
Zurück zum Zitat Morrison VA, Haake RJ, Weisdorf DJ: The spectrum of non-candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72: 78–89. Morrison VA, Haake RJ, Weisdorf DJ: The spectrum of non-candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72: 78–89.
6.
Zurück zum Zitat Cahill BC, Hibbs JR, Savic K, Juni BA, Dosland BM, Edin-Stibbe C, Hertz MI: Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160–1164.CrossRefPubMed Cahill BC, Hibbs JR, Savic K, Juni BA, Dosland BM, Edin-Stibbe C, Hertz MI: Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160–1164.CrossRefPubMed
7.
Zurück zum Zitat Libanore M, Prini E, Mazzetti M, Barchi E, Raise E, Gritti FM, Bonazzi L, Ghinelli F: Invasive Aspergillosis in Italian AIDS patients. Infection 2002; 30: 341–345.CrossRefPubMed Libanore M, Prini E, Mazzetti M, Barchi E, Raise E, Gritti FM, Bonazzi L, Ghinelli F: Invasive Aspergillosis in Italian AIDS patients. Infection 2002; 30: 341–345.CrossRefPubMed
8.
Zurück zum Zitat Wiley JM, Smith N, Leventhal BG, Graham ML, Strauss LC, Hurwitz CA, Modlin J, Mellits D, Baumgardner R, Corden BJ: Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990; 8: 280–286.PubMed Wiley JM, Smith N, Leventhal BG, Graham ML, Strauss LC, Hurwitz CA, Modlin J, Mellits D, Baumgardner R, Corden BJ: Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990; 8: 280–286.PubMed
9.
Zurück zum Zitat Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, doubleblind, multicenter trial. Ann Intern Med 1993; 118: 495–503.PubMed Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, doubleblind, multicenter trial. Ann Intern Med 1993; 118: 495–503.PubMed
10.
Zurück zum Zitat Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.PubMed Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.PubMed
11.
Zurück zum Zitat Boon AP, O’Brien D, Adams DH: 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991; 44: 452–454.CrossRefPubMed Boon AP, O’Brien D, Adams DH: 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991; 44: 452–454.CrossRefPubMed
12.
Zurück zum Zitat Young RC, Bennett JE, Vogel CL, Carbone PP, De Vita VT: Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970; 49: 147–173. Young RC, Bennett JE, Vogel CL, Carbone PP, De Vita VT: Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970; 49: 147–173.
13.
Zurück zum Zitat Meyer RD, Young LS, Armstrong D, Yu B: Aspergillosis complicating neoplastic disease. Am J Med 1973; 54: 6–15.CrossRefPubMed Meyer RD, Young LS, Armstrong D, Yu B: Aspergillosis complicating neoplastic disease. Am J Med 1973; 54: 6–15.CrossRefPubMed
14.
Zurück zum Zitat Fisher BD, Armstrong D, Yu B, Gold JW: Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med 1981; 71: 571–577.CrossRefPubMed Fisher BD, Armstrong D, Yu B, Gold JW: Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med 1981; 71: 571–577.CrossRefPubMed
15.
Zurück zum Zitat Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA: Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis 1985; 131: 115–120.PubMed Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA: Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis 1985; 131: 115–120.PubMed
16.
Zurück zum Zitat Duthie R, Denning DW: Aspergillus fungemia: report of two cases and review. Clin Infect Dis 1995; 20: 598–605.PubMed Duthie R, Denning DW: Aspergillus fungemia: report of two cases and review. Clin Infect Dis 1995; 20: 598–605.PubMed
17.
Zurück zum Zitat Ludwig M, Schneider H, Lohmeyer J, Ermert L, Sziegoleit A, Lommel D, Weidner W: Systemic aspergillosis with predominant genitourinary manifestations in an immunocompetent man: what we can learn from a disastrous follow-up. Infection 2005; 33: 90–92.CrossRefPubMed Ludwig M, Schneider H, Lohmeyer J, Ermert L, Sziegoleit A, Lommel D, Weidner W: Systemic aspergillosis with predominant genitourinary manifestations in an immunocompetent man: what we can learn from a disastrous follow-up. Infection 2005; 33: 90–92.CrossRefPubMed
18.
Zurück zum Zitat Vogeser M, Haas A, Aust D, Ruckdeschel G: Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis 1997; 16: 1–6.CrossRefPubMed Vogeser M, Haas A, Aust D, Ruckdeschel G: Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis 1997; 16: 1–6.CrossRefPubMed
19.
Zurück zum Zitat Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, Buelli M, Picardi M, Allione B, Corvatta L, D’Antonio D, Montillo M, Melillo L, Chierichini A, Cenacchi A, Tonso A, Cudillo L, Candoni A, Savignano C, Bonini A, Martino P, Del Favero A: Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862–870.PubMed Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, Buelli M, Picardi M, Allione B, Corvatta L, D’Antonio D, Montillo M, Melillo L, Chierichini A, Cenacchi A, Tonso A, Cudillo L, Candoni A, Savignano C, Bonini A, Martino P, Del Favero A: Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862–870.PubMed
20.
Zurück zum Zitat Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A: Niaid mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–144.CrossRefPubMed Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A: Niaid mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–144.CrossRefPubMed
21.
Zurück zum Zitat Stevens DA, Lee JY: Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria. Arch Intern Med 1997; 157: 1857–1862.CrossRefPubMed Stevens DA, Lee JY: Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria. Arch Intern Med 1997; 157: 1857–1862.CrossRefPubMed
22.
Zurück zum Zitat Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R: An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173–180.CrossRefPubMed Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R: An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173–180.CrossRefPubMed
23.
Zurück zum Zitat Case records of the massachusetts general hospital. Weekly clinicopathological exercises. Case 37-1976. N Engl J Med 1976; 295: 608–614.CrossRef Case records of the massachusetts general hospital. Weekly clinicopathological exercises. Case 37-1976. N Engl J Med 1976; 295: 608–614.CrossRef
24.
Zurück zum Zitat Weingrad DN, Knapper WH, Gold J, Mertelsmann R: Aspergillus peritonitis complicating perforated appendicitis in adult acute leukemia. J Surg Oncol 1982; 19: 5–8.CrossRefPubMed Weingrad DN, Knapper WH, Gold J, Mertelsmann R: Aspergillus peritonitis complicating perforated appendicitis in adult acute leukemia. J Surg Oncol 1982; 19: 5–8.CrossRefPubMed
25.
Zurück zum Zitat Cohen R, Heffner JE: Bowel infarction as the initial manifestation of disseminated aspergillosis. Chest 1992; 101: 877–879.CrossRefPubMed Cohen R, Heffner JE: Bowel infarction as the initial manifestation of disseminated aspergillosis. Chest 1992; 101: 877–879.CrossRefPubMed
26.
Zurück zum Zitat Marterre WF Jr, Mong AT, Pulito AR: Locally invasive aspergillosis of the bowel. J Pediatr Surg 1992; 27: 1611–1613.CrossRefPubMed Marterre WF Jr, Mong AT, Pulito AR: Locally invasive aspergillosis of the bowel. J Pediatr Surg 1992; 27: 1611–1613.CrossRefPubMed
27.
Zurück zum Zitat Catalano L, Picardi M, Anzivino D, Insabato L, Notaro R, Rotoli B: Small bowel infarction by aspergillus. Haematologica 1997; 82: 182–183.PubMed Catalano L, Picardi M, Anzivino D, Insabato L, Notaro R, Rotoli B: Small bowel infarction by aspergillus. Haematologica 1997; 82: 182–183.PubMed
28.
Zurück zum Zitat Shah SS, Birnbaum BA, Jacobs JE. Disseminated aspergillosis inciting intestinal ischaemia and obstruction. Br J Radiol 2001; 74: 1145–1147.PubMed Shah SS, Birnbaum BA, Jacobs JE. Disseminated aspergillosis inciting intestinal ischaemia and obstruction. Br J Radiol 2001; 74: 1145–1147.PubMed
29.
Zurück zum Zitat Sousa AB, Ferreira G, Veiga J, Carvalho A: Clinical picture: bowel infarction due to aspergillosis. Lancet 2002; 359: 210.CrossRefPubMed Sousa AB, Ferreira G, Veiga J, Carvalho A: Clinical picture: bowel infarction due to aspergillosis. Lancet 2002; 359: 210.CrossRefPubMed
30.
Zurück zum Zitat Tresallet C, Nguyen-Thanh Q, Aubriot-Lorton MH, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R: Small-bowel infarction from disseminated aspergillosis. Dis Colon Rectum 2004; 47: 1515–1518.PubMed Tresallet C, Nguyen-Thanh Q, Aubriot-Lorton MH, Spence D, Herbrecht R, Pagano L, Kibbler C, Kcrmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R: Small-bowel infarction from disseminated aspergillosis. Dis Colon Rectum 2004; 47: 1515–1518.PubMed
31.
Zurück zum Zitat Vogeser M, Wanders A, Haas A, Ruckdeschel G: A four-year review of fatal Aspergillosis. Eur J Clin Microbiol Infect Dis 1999; 18: 42–45.CrossRefPubMed Vogeser M, Wanders A, Haas A, Ruckdeschel G: A four-year review of fatal Aspergillosis. Eur J Clin Microbiol Infect Dis 1999; 18: 42–45.CrossRefPubMed
32.
Zurück zum Zitat Kami M, Hori A, Takaue Y, Mutou Y: The gastrointestinal tract is a common target of invasive aspergillosis in patients receiving cytotoxic chemotherapy for hematological malignancy. Clin Infect Dis 2002; 35: 105–106.CrossRefPubMed Kami M, Hori A, Takaue Y, Mutou Y: The gastrointestinal tract is a common target of invasive aspergillosis in patients receiving cytotoxic chemotherapy for hematological malignancy. Clin Infect Dis 2002; 35: 105–106.CrossRefPubMed
33.
Zurück zum Zitat Horvath JA, Dummer S: The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171–178.CrossRefPubMed Horvath JA, Dummer S: The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171–178.CrossRefPubMed
34.
Zurück zum Zitat Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, Ossenkoppele GJ, Thijs LG, Huijgens PC: Outcome of icu treatment in invasive aspergillosis. Intensive Care Med 1996; 22: 1315–1322.CrossRefPubMed Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, Ossenkoppele GJ, Thijs LG, Huijgens PC: Outcome of icu treatment in invasive aspergillosis. Intensive Care Med 1996; 22: 1315–1322.CrossRefPubMed
35.
Zurück zum Zitat Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147.PubMed Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147.PubMed
36.
Zurück zum Zitat Kaiser L, Hugenin T, Lew PD, Chapuis B, Pittet D: Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188–194.CrossRef Kaiser L, Hugenin T, Lew PD, Chapuis B, Pittet D: Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188–194.CrossRef
37.
Zurück zum Zitat Abbasi S, Shenep JL, Hughes WT, Flynn PM: Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999; 29: 1210–1219.CrossRefPubMed Abbasi S, Shenep JL, Hughes WT, Flynn PM: Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999; 29: 1210–1219.CrossRefPubMed
38.
Zurück zum Zitat Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P, De Pauw B, Denning DW: Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000; 30: 41–46.CrossRefPubMed Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P, De Pauw B, Denning DW: Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000; 30: 41–46.CrossRefPubMed
39.
Zurück zum Zitat Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L, Tedeschi A, Magliano E, Morra E: Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001; 68: 231–236.CrossRefPubMed Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L, Tedeschi A, Magliano E, Morra E: Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001; 68: 231–236.CrossRefPubMed
40.
Zurück zum Zitat Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(Suppl. B): 73–82.PubMed Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(Suppl. B): 73–82.PubMed
41.
Zurück zum Zitat Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR: Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260.CrossRef Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR: Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260.CrossRef
42.
Zurück zum Zitat Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571.CrossRefPubMed Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571.CrossRefPubMed
43.
Zurück zum Zitat Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, De Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.CrossRefPubMed Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, De Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.CrossRefPubMed
44.
Zurück zum Zitat Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, Van Burik JA, Laverdiere M, Safrin S, Wingard JR: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366.CrossRefPubMed Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, Van Burik JA, Laverdiere M, Safrin S, Wingard JR: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366.CrossRefPubMed
45.
Zurück zum Zitat Lin S, Schranz J, Teutsch S: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.CrossRefPubMed Lin S, Schranz J, Teutsch S: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.CrossRefPubMed
46.
Zurück zum Zitat Morrison VA, Haake RJ, Weisdorf DJ: Non-candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96: 497–503.CrossRefPubMed Morrison VA, Haake RJ, Weisdorf DJ: Non-candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96: 497–503.CrossRefPubMed
47.
Zurück zum Zitat Prescott RJ, Harris M, Banerjee SS: Fungal infections of the small and large intestine. J Clin Pathol 1992; 45: 806–811.CrossRefPubMed Prescott RJ, Harris M, Banerjee SS: Fungal infections of the small and large intestine. J Clin Pathol 1992; 45: 806–811.CrossRefPubMed
48.
Zurück zum Zitat Myoken Y, Sugata T, Kyo T, Kyo T, Fujihara M, Kohara T, Katsu M, Tamura M, Mikami Y: Invasive Aspergillus stomatitis in patients with acute leukemia: report of 12 cases. Clin Infect Dis 2001; 33: 1975–1980.CrossRefPubMed Myoken Y, Sugata T, Kyo T, Kyo T, Fujihara M, Kohara T, Katsu M, Tamura M, Mikami Y: Invasive Aspergillus stomatitis in patients with acute leukemia: report of 12 cases. Clin Infect Dis 2001; 33: 1975–1980.CrossRefPubMed
49.
Zurück zum Zitat Nylander WA Jr: The acute abdomen in the immunocompromised host. Surg Clin North Am 1988; 68: 457–470.PubMed Nylander WA Jr: The acute abdomen in the immunocompromised host. Surg Clin North Am 1988; 68: 457–470.PubMed
50.
Zurück zum Zitat Johnson H, Smith TJ, Desforges J: Cytosine-arabinoside-induced colitis and peritonitis: nonoperative management. J Clin Oncol 1985; 3: 607–612.PubMed Johnson H, Smith TJ, Desforges J: Cytosine-arabinoside-induced colitis and peritonitis: nonoperative management. J Clin Oncol 1985; 3: 607–612.PubMed
51.
Zurück zum Zitat Vlasveld LT, Zwaan FE, Fibbe WE, Fibbe WE, Tjon RT, Tham TA, Kluin PM, Willemze R: Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine. Ann Hematol 1991; 62: 129–134.CrossRefPubMed Vlasveld LT, Zwaan FE, Fibbe WE, Fibbe WE, Tjon RT, Tham TA, Kluin PM, Willemze R: Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine. Ann Hematol 1991; 62: 129–134.CrossRefPubMed
52.
Zurück zum Zitat Starnes HF Jr, Moore FD Jr, Mentzer S, Osteen RT, Steele GD Jr, Wilson RE: Abdominal pain in neutropenic cancer patients. Cancer 1986; 57: 616–621.CrossRefPubMed Starnes HF Jr, Moore FD Jr, Mentzer S, Osteen RT, Steele GD Jr, Wilson RE: Abdominal pain in neutropenic cancer patients. Cancer 1986; 57: 616–621.CrossRefPubMed
53.
Zurück zum Zitat Chirletti P, Barillari P, Sammartino P, Cardi M, Caronna R, Arcese W, Petti C, Stipa V: The surgical choice in neutropenic patients with hematological disorders and acute abdominal complications. Leuk Lymphoma 1993; 9: 237–241.CrossRefPubMed Chirletti P, Barillari P, Sammartino P, Cardi M, Caronna R, Arcese W, Petti C, Stipa V: The surgical choice in neutropenic patients with hematological disorders and acute abdominal complications. Leuk Lymphoma 1993; 9: 237–241.CrossRefPubMed
54.
Zurück zum Zitat Gomez L, Martino R, Rolston KV: Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis 1998; 27: 695–699.CrossRefPubMed Gomez L, Martino R, Rolston KV: Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis 1998; 27: 695–699.CrossRefPubMed
55.
Zurück zum Zitat Weinberger M, Hollingsworth H, Feuerstein IM, Young NS, Pizzo PA: Successful surgical management of neutropenic enterocolitis in two patients with severe aplastic anemia. Case reports and review of the literature. Arch Intern Med 1993; 153: 107–113.CrossRefPubMed Weinberger M, Hollingsworth H, Feuerstein IM, Young NS, Pizzo PA: Successful surgical management of neutropenic enterocolitis in two patients with severe aplastic anemia. Case reports and review of the literature. Arch Intern Med 1993; 153: 107–113.CrossRefPubMed
56.
Zurück zum Zitat Hori A, Kami M, Kishi Y, Machida U, Matsumura T, Kashima T: Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002; 50: 175–182.CrossRefPubMed Hori A, Kami M, Kishi Y, Machida U, Matsumura T, Kashima T: Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002; 50: 175–182.CrossRefPubMed
Metadaten
Titel
Primary Invasive Aspergillosis of the Digestive Tract: Report of Two Cases and Review of the Literature
verfasst von
P. Eggimann
J.-C. Chevrolet
M. Starobinski
P. Majno
M. Totsch
B. Chapuis
D. Pittet
Publikationsdatum
01.12.2006
Verlag
Urban & Vogel
Erschienen in
Infection / Ausgabe 6/2006
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-006-5660-0

Weitere Artikel der Ausgabe 6/2006

Infection 6/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.